Recent recommendations by the Health and Human Services Department have the potential to reclassify cannabis as a Schedule 3 drug, opening the doors for more scientific research, improved banking options, and greater acceptance within the medical community. At the forefront of this dynamic landscape is Portland, Maine-based Nova Analytic Labs, a company founded in 2020… Continue reading Navigating a New Era in Cannabis Testing: An In-depth Look at Nova Analytic Labs and an Exclusive Interview with CEO Chris Altomare